Tirzepatide Activates Brown Fat in Obese Mice, Suggesting New Metabolic Benefits

A recent study found that tirzepatide—marketed as Mounjaro and Zepbound—stimulated the body’s calorie‑burning brown fat in obese mice. The drug’s known appetite‑suppressing effects may be complemented by this metabolic action, potentially explaining its strong weight‑loss and blood‑sugar‑lowering outcomes. Researchers caution that human confirmation is needed before drawing definitive conclusions. If replicated in people, the finding could broaden the therapeutic appeal of tirzepatide and guide the development of more comprehensive obesity and diabetes treatments.